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ABSTRACT
I am developing a novel cell-based small-molecule screening approach that can identify inhibitors of any non-essential protein function through a surrogate synthetic lethal phenotype in the baker's yeast, Saccharomyces cerevisiae. Synthetic lethality (SL) is a form of genetic enhancement in which two mutations are lethal in combination, but the corresponding individual mutants are viable. Thus, a sensitized yeast strain carrying a mutation that is synthetic lethal with a gene of interest will be inviable in the presence of a chemical inhibitor of the target protein. Systematic genome-wide genetic screens can simultaneously determine all the synthetic lethal genetic interactions for a given gene deletion in yeast. I will adopt this strategy to determine the SL partners for the yeast genes SCH9, the yeast homologue of the human oncogene AKT, and TEP1, the yeast equivalent of the human tumor suppressor PTEN. Selected confirmed synthetic lethal mutants will be used as sensitized strains to screen a commercial small-molecule library for inhibitors of the corresponding proteins. I have developed a yeast-based high-throughput screening platform to screen the Maybridge small-molecule library. Compounds derived from the initial chemical genetic screen will be validated biochemically and, ultimately, tested on mammalian cells for activity against the human homologues. 
SUBJECT TERMS
INTRODUCTION Project summary:
Cell-based screening relies on an observable phenotype to identify potential hits. Unfortunately, only a small fraction of metazoan genes reveal an easily identifiable phenotype when deleted. For example, only 40% of Saccharomyces cerevisiae genes exhibit a growth defect when deleted in haploid cells at standard growth conditions (Winzeler, Shoemaker et al. 1999) . Similarly, in the model organism C. elegans, approximately half of null mutations exhibit a wild type phenotype (Park and Horvitz 1986) . In order to survey the maximum number of chemical-genetic interactions, an easily observable reporter phenotype is required.
I am developing a novel cell-based small-molecule screening approach that can identify inhibitors of any non-essential protein function through a surrogate synthetic lethal phenotype in the baker's yeast, Saccharomyces cerevisiae. Synthetic lethality (SL) is a form of genetic enhancement in which two mutations are lethal in combination, but the corresponding individual mutants are viable. Thus, a sensitized yeast strain carrying a mutation that is synthetic lethal with a gene of interest will be inviable in the presence of a chemical inhibitor of the target protein. Systematic genome-wide genetic screens have been developed to simultaneously determine all the synthetic lethal genetic interactions for a given gene deletion in yeast. I will adopt this strategy to determine the SL partners for the yeast genes SCH9, the closest yeast homologue to the human oncogene AKT, and TEP1, the yeast equivalent of the human tumor suppressor PTEN. Selected synthetic lethal mutants will then be used as sensitized strains to screen commercial smallmolecule libraries for inhibitors of the corresponding proteins.
Large-scale library screening requires concurrent development of a yeast-based high-throughput screening platform. Compounds derived from the initial chemical genetic screen will be validated biochemically and, ultimately, tested on mammalian cells for activity against the human homologues. To achieve this, four main aims will be pursued: Aim 1. High throughput infrastructure development (months1-9). Cherry -picked a mini-array of putative "hit" compounds from the Maybridge library and tested for differential activity using a dose response assay. SGA analysis of tep1∆ mutant. Confirmed a single genetic interaction with fun12∆. Screened SCH9 SL reporter strains against LOPAC and ChemDiv libraries. Pilot assay for chemical-genetic fingerprinting.
Year Three:
In order to exhaustively define the genetic interactions surrounding SCH9 and TEP1, I undertook a DSLAM analysis of the corresponding mutants against the deletion set. DSLAM is a modified SGA analysis that uses the heterozygous diploid yeast collection and relies on transformation of plasmid DNA and recombination to create the double mutants (Pan, Yuan et al. 2004 ). The assay is a liquid growth competition that is analyzed by microarray. The advantages of DSLAM are decreased genetic suppression of starting strains due to heterozygosity, fewer false-positive interactions from mating defective mutants and increased signal sensitivity from the microarray. DSLAM produced 5 new confirmed hits, including an additional ribosomal subunit, RPS22A (Fig 1.) . Interestingly, there was virtually no overlap between the two assay types. Additionally, DSLAM failed to uncover any of the published genetic interactions. It is clear that these two genetic techniques are powerful, complementary systems for probing genetic interactions on a genome-wide scale, though the coverage is still incomplete.
I next undertook a DSLAM analysis of tep1∆. Previous SGA analysis only uncovered a single genetic interaction between tep1∆ and fun12∆. DSLAM produced an additional 13 interactions (Table 1. ), but did not recapitulate the interaction with fun12, further indicating that the two assays complement each other. The tep1 DLSAM interactions are being confirmed by mating and tetrad dissection currently.
In order to increase our chemical space and diversity for the synthetic lethal assay, we acquired an aliquot of the 2000 compound Spectrum library from MicroSource. This library is biased toward natural products and provides a further platform for studying chemical synthetic lethal interactions. A preliminary screen of rpl9b∆ against the Spectrum library produced a single differential hit compared to the wildtype strain: Clorpropham, an insecticide (Fig 2. ). Unfortunately, Clorpropham had no effect on a gpr1∆ mutant strain, suggesting that SCH9 is not the target (data not shown). We have ordered Chlorpropham as part of a restock and can perform a secondary, size phenotype assay to test SCH9as a target.
Spectrum Library
In order to demonstrate the proof of principle for synthetic lethal chemogenetic analysis, I turned to a system in which the target had been previously determined. The immunosuppressant drug Cyclosporin A forms a complex with the cyclophillins and inhibits the phosphatase, calcineurin (Liu, Farmer et al. 1991) . The yeast gene CNB1 encodes the homologue for the regulatory subunit of calcineurin, the functional target of Cyclosporin A. Calcineurin is a non-essential gene in yeast (and humans) and the genetic interactions for CNB1 are well described (Parsons, Brost et al. 2004 ), thus Cyclosporin A makes an excellent model system to study surrogate genetic interactions using small molecules. Cyclosporin A is contained within the Spectrum library, thus providing a test case for screening sensitized strains as reporters for Cnb1 inhibition. A preliminary screen of fks1∆ showed a strong differential activity against Cyclosporine A as predicted by the genetic profile (Fig 3.) . Since Cyclosporin A appeared as one of the strongest hits in an fks1∆ background, I went on to determine if Cyclosporin A would produce a unique profile corresponding to its genetic interactions. I screened several additional known cnb1-interacting mutants among a panel of mutants that had no known genetic interactions. The screen was able to reliably identify the known genetic interactors while none of the other strains exhibited any significant bioactivity in the presence of Cyclosporin A (Fig. 4) . shown in blue (Z score >4). Cytotoxic compounds are shown in yellow (<2SD from cytotoxic control). CNB1 genetic interactors are denoted with ovals. Note: gas1, ypt6 and ric1 mutants were slow growing and were measured at two time points to capture the maximum dynamic range (both time points are shown). Wildtype reference strain is denoted with an arrow.
Conclusions
I was able to successfully map the genetic interactions surrounding the yeast kinase SCH9 and, to a lesser degree, the phosphatase Tep1. There are a number of challenges that still exist in defining the genetic network surrounding any given gene in the Saccharomyces cerevisiae genome. Neither method employed, SGA or DSLAM, provided comprehensive (or overlapping) coverage. The inability to pick out previously determined interactions indicates false negative interactions remain an Achilles heel of both assays. In spite of these shortcomings, genome-wide genetic interaction mapping is a powerful tool for elucidating genetic networks.
The proof of principle assays, using both the analogue sensitive kinase allele of SCH9 (year one) and the CNB1-Cyclosporin A model system; demonstrate the validity of the surrogate synthetic lethal approach. It is clear that sensitized strains can be used as reporters for small molecule inhibitors of non-essential proteins. The sensitized strains allow interrogation of chemical space that would be invisible in wild type cells. One of the features of the system is the ability to enhance the phenotype from a subtle cellular effect that may be difficult to quantify in a high throughput format, such as cell size, to a death phenotype that has a wide dynamic range and is easy to measure.
While the small molecule screens were ultimately unsuccessful in finding a specific inhibitor of Sch9, they were a valuable resource and ultimately bore fruit for a related project. The data collected from the differential screen of the 50,000 compound Maybridge small molecule library allowed us to filter and select a subset of compounds that have bioactivity against yeast. We built a sub library of 1500 compounds which we are naming the SacchPAC, for Saccharomyces Pharmacologically Active Compounds that will be made available to the yeast community for pilot phenotype screens.
Unfortunately, since the preliminary small molecule screens produced no viable leads I was unable to proceed with aims 3 and 4 as outlined in the statement of work. The problems with the genetic assays that were encountered originally were ultimately resolved; however, the chemical space of the library that was available did not encompass backbones that specifically interfered with Sch9 function. The results with the Cyclosporine A proof-of-principle make me hopeful that the TEP1 genetic interactor screen will be successful when the network is fully defined. Using the Synthetic Genetic Array (SGA) approach, we determined the SL partner genes for a deletion of SCH9, a kinase involved in size control in yeast and the closest homolog to human Akt. As a proof-of-principle, we constructed an analog-sensitive (AS) SCH9 allele that is specifically sensitive to the purine analog NM-PP1. AS-SCH9 strains carrying gene deletions that are SL with sch9∆ were inviable in the presence of NM-PP1 but the single mutants, or the AS strain alone, grew in the presence of the drug, demonstrating the validity of the approach. We developed a high-throughput liquid comparative growth assay and screened the 50,000-molecule Maybridge library for Sch9 inhibitors using our chemical-genetic trap. The first iteration returned 77 compounds specific to the sensitized strain. Initial hits were confirmed and subjected to subsequent rounds of screening against non-overlapping sensitized strains. Confirmed hits will be analyzed in secondary phenotype screens.
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